Myths vs facts: CYP2D6 and Blutzucker

CYP2D6 is a drug-metabolizing enzyme, not a direct regulator of blood glucose. Myths often claim that certain CYP2D6 variants raise or lower blood sugar – there is no robust evidence for this. The fact is: CYP2D6 metabolizes many medications (e.g., beta-blockers, antidepressants, opioids) that can indirectly affect glucose metabolism. Some studies show weak associations between CYP2D6 polymorphisms and diabetes risk, but effect sizes are small, ancestry-dependent, and not clinically actionable. Consumer DNA tests frequently overstate the relevance of such variants for blood sugar. Fasting glucose and insulin sensitivity are primarily influenced by genes like TCF7L2, PPARG, KCNJ11 and lifestyle factors. Relying solely on CYP2D6 analysis for blood sugar management is scientifically unsupported. Caution: medication dosages should never be adjusted based solely on genetic test results without physician oversight.